News

Filter by:
Reset
  • Press Release

AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024
  • Press Release

AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081
  • Press Release

AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)
  • Press Release

AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
  • Press Release

AAVantgarde announces 3 oral presentations at ESGCT 2024
  • Press Release

AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B
  • Press Release

AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
  • Press Release

AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit
  • Press Release

AAVantgarde announces updated NHP data for its Stargardt program to be presented at ARVO 2024
  • Press Release

AAVantgarde presents large animal models preclinical data at ASGCT 2024
  • Press Release

AAVantgarde appoints Nina (Ekaterini) Kotsopoulou, Ph.D., as Chief Technical Officer
  • Press Release

AAVantgarde Appoints Dr. Peter K. Kaiser to the Board of Directors
  • Press Release

AAVantgarde Appoints Michael Heffernan as Chairman of its Board of Directors
  • Press Release

AAVantgarde Appoints Dr. Doug Kerr to the Board of Directors
  • Press Release

AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic